Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings

Detects cell-free DNA (cfDNA) circulating in the blood by whole-genome sequencing (WGS). It also detects cfDNA containing epigenetic marks by cell-free methylated DNA immunoprecipitation and high throughput sequencing assays and may determine the concordance of genomic alterations between tumour tissue (if available) and matched plasma samples by WGS.

PEM produces high-sensitivity images of breasts with low levels of F-18 FDG.